KR102013086B1 - 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법 - Google Patents

알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법 Download PDF

Info

Publication number
KR102013086B1
KR102013086B1 KR1020187009383A KR20187009383A KR102013086B1 KR 102013086 B1 KR102013086 B1 KR 102013086B1 KR 1020187009383 A KR1020187009383 A KR 1020187009383A KR 20187009383 A KR20187009383 A KR 20187009383A KR 102013086 B1 KR102013086 B1 KR 102013086B1
Authority
KR
South Korea
Prior art keywords
cells
alpha
compound
receptor
alkyl
Prior art date
Application number
KR1020187009383A
Other languages
English (en)
Korean (ko)
Other versions
KR20180040710A (ko
Inventor
다니엘 더블유. 길
존 이. 도넬로
로렌 엠.비. 러스
비나 비스워나스
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20180040710A publication Critical patent/KR20180040710A/ko
Application granted granted Critical
Publication of KR102013086B1 publication Critical patent/KR102013086B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187009383A 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법 KR102013086B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37412410P 2010-08-16 2010-08-16
US61/374,124 2010-08-16
PCT/US2011/047426 WO2012024161A1 (en) 2010-08-16 2011-08-11 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137006669A Division KR101847669B1 (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197023782A Division KR20190097323A (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Publications (2)

Publication Number Publication Date
KR20180040710A KR20180040710A (ko) 2018-04-20
KR102013086B1 true KR102013086B1 (ko) 2019-08-21

Family

ID=44543836

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187009383A KR102013086B1 (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
KR1020137006669A KR101847669B1 (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
KR1020197023782A KR20190097323A (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137006669A KR101847669B1 (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
KR1020197023782A KR20190097323A (ko) 2010-08-16 2011-08-11 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Country Status (18)

Country Link
US (5) US8575207B2 (ru)
EP (2) EP3332782A1 (ru)
JP (3) JP5938407B2 (ru)
KR (3) KR102013086B1 (ru)
CN (3) CN108272797B (ru)
AU (1) AU2011292296B2 (ru)
BR (1) BR112013003590A2 (ru)
CA (1) CA2808307C (ru)
DK (1) DK2605771T3 (ru)
ES (1) ES2676194T3 (ru)
HK (2) HK1256823A1 (ru)
HU (1) HUE038366T2 (ru)
PL (1) PL2605771T3 (ru)
PT (1) PT2605771T (ru)
RU (2) RU2016134989A (ru)
SI (1) SI2605771T1 (ru)
TR (1) TR201809456T4 (ru)
WO (1) WO2012024161A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014332A1 (en) * 2009-07-30 2011-02-03 Allergan, Inc. Selective alpha 2b/2c agonists
PT2605771T (pt) 2010-08-16 2018-07-09 Allergan Inc Método de ativação de células t reguladoras com agonistas dos recetores adrenérgicos alfa-2b
US20150313896A1 (en) * 2013-07-26 2015-11-05 Galderma Research & Development Method for treating cell proliferation disorders
RU2691412C2 (ru) * 2015-02-24 2019-06-13 Дзе Боард Оф Трастис Оф Дзе Юниверсити Оф Иллинойс Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US20180250369A1 (en) * 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
WO2017062491A1 (en) * 2015-10-05 2017-04-13 Jing-Feng Huang Therapeutic compositions for the treatment of dry eye and related ocular surface diseases
EP3445372A4 (en) * 2016-04-22 2020-03-25 Viking Therapeutics, Inc. USE OF BETA-AGONISTS OF THYROID HORMONES
JP2020523406A (ja) 2017-05-19 2020-08-06 オクジェン アイエヌシー． 眼科用組成物および使用方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036162A2 (en) 2000-11-01 2002-05-10 Allergan, Inc. Compositions for treatment of ocular neovascularization and neural injury
WO2002076950A2 (en) 2001-03-21 2002-10-03 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
WO2003099289A2 (en) 2002-05-21 2003-12-04 Allergan, Inc. Compositions and their uses for alleviating pain
WO2009020578A1 (en) 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
WO2009052075A2 (en) 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US20090306398A1 (en) 2008-06-09 2009-12-10 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US20090306161A1 (en) 2008-06-09 2009-12-10 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
WO2011014332A1 (en) 2009-07-30 2011-02-03 Allergan, Inc. Selective alpha 2b/2c agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2835423A1 (de) 1978-08-12 1980-03-06 Hoechst Ag Beton- und moertelzusatzmittel und dessen verwendung
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
BRPI0414277A (pt) 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
AU2005290075A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
KR101202066B1 (ko) * 2004-09-28 2012-11-15 알러간, 인코포레이티드 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
AU2007332641A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
MX2010001351A (es) 2007-08-03 2010-06-25 Mill Steel Co Aparato para determinar el perfil de calibre para material enrollado plano.
US8809379B2 (en) * 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
BRPI0906875A2 (pt) * 2008-01-18 2015-07-07 Allergan Inc Agentes adrenérgicos alfa 2 de subtipo seletivo de oxazolidina e tiazolidina e métodos para uso dos mesmos
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
PT2605771T (pt) 2010-08-16 2018-07-09 Allergan Inc Método de ativação de células t reguladoras com agonistas dos recetores adrenérgicos alfa-2b

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036162A2 (en) 2000-11-01 2002-05-10 Allergan, Inc. Compositions for treatment of ocular neovascularization and neural injury
WO2002076950A2 (en) 2001-03-21 2002-10-03 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
WO2003099289A2 (en) 2002-05-21 2003-12-04 Allergan, Inc. Compositions and their uses for alleviating pain
WO2009020578A1 (en) 2007-08-06 2009-02-12 Schering Corporation Alpha2c adrenoreceptor agonists
WO2009052075A2 (en) 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US20090306398A1 (en) 2008-06-09 2009-12-10 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
US20090306161A1 (en) 2008-06-09 2009-12-10 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
WO2011014332A1 (en) 2009-07-30 2011-02-03 Allergan, Inc. Selective alpha 2b/2c agonists

Also Published As

Publication number Publication date
US20180071259A1 (en) 2018-03-15
JP6250728B2 (ja) 2017-12-20
RU2016134989A (ru) 2018-12-11
US20120041031A1 (en) 2012-02-16
WO2012024161A1 (en) 2012-02-23
CA2808307C (en) 2022-06-21
KR20130108301A (ko) 2013-10-02
PL2605771T3 (pl) 2018-10-31
ES2676194T3 (es) 2018-07-17
US20160158199A1 (en) 2016-06-09
EP2605771B1 (en) 2018-04-04
EP3332782A1 (en) 2018-06-13
JP5938407B2 (ja) 2016-06-22
EP2605771A1 (en) 2013-06-26
BR112013003590A2 (pt) 2016-05-31
JP2013534246A (ja) 2013-09-02
CN114073696A (zh) 2022-02-22
CA2808307A1 (en) 2012-02-23
JP2016117781A (ja) 2016-06-30
DK2605771T3 (en) 2018-07-16
US10251865B2 (en) 2019-04-09
TR201809456T4 (tr) 2018-07-23
CN108272797A (zh) 2018-07-13
KR20190097323A (ko) 2019-08-20
PT2605771T (pt) 2018-07-09
US9545394B2 (en) 2017-01-17
CN103153296B (zh) 2018-02-13
AU2011292296A1 (en) 2013-03-14
US8575207B2 (en) 2013-11-05
CN108272797B (zh) 2021-04-27
AU2011292296B2 (en) 2015-09-03
US9289420B2 (en) 2016-03-22
SI2605771T1 (sl) 2018-09-28
JP2018027984A (ja) 2018-02-22
RU2016134989A3 (ru) 2020-02-17
CN103153296A (zh) 2013-06-12
US20170079956A1 (en) 2017-03-23
KR20180040710A (ko) 2018-04-20
HUE038366T2 (hu) 2018-10-29
RU2013110877A (ru) 2014-09-27
US20140066483A1 (en) 2014-03-06
RU2599495C2 (ru) 2016-10-10
HK1258043A1 (zh) 2019-11-01
KR101847669B1 (ko) 2018-05-24
HK1256823A1 (zh) 2019-10-04
JP6509307B2 (ja) 2019-05-08

Similar Documents

Publication Publication Date Title
KR102013086B1 (ko) 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법
WO2011021833A2 (ko) 염증 예방 또는 치료용 조성물
JP2011057700A (ja) 神経変性を処置するためのα２Ｂまたは２Ｂ／２Ｃアドレナリン受容体アゴニスト
AU2015255182B2 (en) Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant